Circulating levels of tumour necrosis factor, interleukin 6 and proteolytic activity in a murine model of burn and infection

Burns

Volumn 22, Issue 7, 1996, Pages 524-530

  Neely, A N ^a   Hoover, D L ^a   Holder, I A ^a   Cross, A S ^a  

^a SHRINERS HOSPITALS FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; CYTOKINE; INTERLEUKIN 6; PROTEINASE; PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BURN; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; MORTALITY; MOUSE; NONHUMAN; PROTEIN DEGRADATION; SEPSIS;

EID: 0030298188     PISSN: 03054179     EISSN: None     Source Type: Journal    
DOI: 10.1016/0305-4179(96)00029-0     Document Type: Article

References (41)

1. 1 Clowes GHA Jr. Stresses, mediators, and responses of survival. In: Clowes Jr GHA (ed) The Physiological Basis of Therapy. New York: Marcel Dekker, 1988; pp 1-53.
2. 2 Coleman RW. The role of plasma proteases in septic shock. N Engl J Med 1989; 320: 1207-1209.
3. 3 Billiau A, Vandekerckhove F. Cytokines and their interactions with other inflammatory mediators in the pathogenesis of sepsis and septic shock. Eur J Clin Invest 1991; 21: 559-573.
4. 4 Miller RG, Neely AN. Surgical trauma, Candida infection and serum proteolytic activity. J Surg Res 1992; 53: 263-267.
5. 5 deBoer JP, Creasey AA, Chang A et al. Activation of the complement system in baboons challenged with live Escherichia coli: correlation with mortality and evidence for a biphasic activation pattern. Infect Immunol 1993; 61: 4293-4301.
6. 6 Rodriguez JL, Miller CG, Garner WL et al. Correlation of the local and systemic cytokine response with clinical outcome following thermal injury. J Trauma 1993; 34: 684-695.
7. 7 Neely AN, Miller RG, Holder IA. Proteolytic activity and fatal gram-negative sepsis in burned mice: effect of exogenous proteinase inhibition. Infect Immunol 1994; 62: 2158-2164.
8. 8 Aasen AO, Smith-Erichsen N, Amundsen E. Uncontrolled plasma proteolysis: a major threat to the septicemic patient. Resuscitation 1986; 14: 33-42.
9. 9 Risberg B, Medegard A, Heideman M et al. Early activation of humoral proteolytic systems in patients with multiple trauma. Crit Care Med 1986; 14: 917-925.
10. 10 Neely AN, Holder IA. The effect of proteolytic activity on the virulence of Candida albicans in burned mice. Infect Immunol 1990; 58: 1527-1531.
11. 11 Neely AN, Nathan P, Highsmith RF. Plasma proteolytic activity following burns. J Trauma 1988; 28: 362-367.
12. 12 Neely AN, Warden GD, Rieman M, Friedberg DL, Holder IA. Components of the increased circulating proteolytic activity in pediatric burn patients. J Trauma 1992; 33: 807-812.
13. 13 Duswald K-H, Jochum M, Schramm W, Fritz H. Released granulocytic elastase: an indicator of pathobiochemical alterations in septicemia after abdominal surgery. Surgery 1985; 98: 892-899.
14. 14 Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. J Exp Med 1989; 169: 333-338.
15. 15 Hack CE, DeGroot ER, Felt-Bersma RJF et al. Increased plasma levels of interleukin-6 in sepsis. Blood 1989; 74: 1704-1710.
16. 16 Mayoral JL, Schweich CJ, Dunn DL. Decreased tumor necrosis factor production during the initial stages of infection correlates with survival during murine gram-negative sepsis. Arch Surg 1990; 125: 24-28.
17. 17 Dofferhoff ASM, Bom VJJ, deVries-Hospers HG et al. Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor and acute-phase proteins during the treatment of severe sepsis in humans. Crit Care Med 1992; 20: 185-192.
18. 18 Teti G, Mancuso G, Tomasllo F, Chiofalo MS. Production of tumor necrosis factor-α and interleukin-6 in mice infected with group B streptococci. Circ Shock 1992; 38: 138-144.
19. 19 Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119: 771-778.
20. 20 Moscovitz H, Shofer F, Mignott H, Behrman A, Kilpatrick L. Plasma cytokine determinations in emergency department patients as a predictor of bacteremia and infectious disease severity. Crit Care Med 1994; 22: 1102-1107.
21. 21 Marano MA, Fong Y, Moldawer LL et al. Serum cachectin/ tumor necrosis factor in critically ill patients with burns correlates with infection and mortality. Surg Gynecol Obstet 1990; 170: 32-38.
22. 22 Guo Y, Dickerson C, Chrest FJ, Adler WH, Munster AM, Winchurch RA. Increased levels of circulating interleukin-6 in burn patients. Clin Immunol Immunpathol 1990; 54: 361-371.
23. 23 Nijsten MWN, Hack CE, Helle M, ten Duis HJ, Klasen HJ, Aarden LA. Interleukin-6 and its relation to the humoral immune response and clinical parameters in burned patients. Surgery 1991; 109: 671-767.
24. 24 Schluter B, Konig B, Bergmann U, Muller FE, Konig W. Interleukin-6 - a potential mediator of lethal sepsis after major thermal trauma: evidence for increased IL-6 production by peripheral blood mononuclear cells. J Trauma 1991; 31: 1663-1669.
25. 25 Ueyama M, Maruyama I, Osame M, Sawada Y. Marked increase in plasma interleukin-6 in burn patients. J Lab Clin Med 1992; 120: 693-698.
26. 26 Kowal-Vern A, Walenga JM, Hoppensteadt D, Sharp-Pucci M, Gamelli RL. Interleukin-2 and interleukin-6 in relation to burn wound size in the acute phase of thermal injury. J Am Coll Surg 1994; 178: 357-362.
27. 27 Drost AC, Burleson DG, Gioffi Jr WG, Mason Jr AD, Pruitt Jr BA. Plasma cytokines after thermal injury and their relationship to infection. Ann Surg 1993; 218: 74-78.
28. 28 Stieritz DD, Holder IA. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: description of a burned mouse model. J Infect Dis 1975; 131: 688-691.
29. 29 Kelly NM, Young L, Cross AS. Differential induction of tumor necrosis factor by bacteria expressing rough and smooth lipopolysaccharide phenotypes. Infect Immunol 1991; 59: 4491-4496.
30. 30 Helle M, Boeije L, Aarden LA. Functional discrimination between interleukin 6 and interleukin 1. Eur J Immunol 1988; 18: 1535-1540.
31. 31 Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. N Engt J Med 1987; 316: 379-385.
32. 32 Natanson C, Hoffman WD, Suffredini AF, Eichacker PQ, Danner RL. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 1994; 120: 771-783.
33. 33 Kelly NM, Cross AS. Interleukin-6 is a better marker of lethality than tumor necrosis factor in endotoxin treated mice. FEMS Microbiol Immunol 1992; 89: 317-322.
34. 34 Zanetti G, Heumann D, Gerain J et al. Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. J Immunol 1992; 148: 1890-1997.
35. 35 Calandra T, Baumgartner JD, Grau GE, Wu MM, Lambert PH, Schellekens J. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-α in the serum of patients with septic shock. J Infect Dis 1990; 161: 982-987.
36. 36 Cannon JG, Friedberg JS, Gelfand JA, Tompkins RG, Burke JF, Dinarello CA. Circulating interleukin-1β and tumor necrosis factor-α concentrations after burn injury in humans. Crit Care Med 1992; 20: 1414-1419.
37. 37 Harpel PC. Blood proteolytic enzyme inhibitors: their role in modulating blood coagulation and fibrinolyric enzyme pathways. In: Coleman RW, Hirsh H, Marder VJ, Salzman EW (eds) Hemostasis and Thrombosis Basic Principles and Clinical practice, 2nd edn. New York: Lippincott, 1987; pp 219-234.
38. 38 McMichan JC, Rosengarten DS, Philipp E. Prophylaxis of post-traumatic pulmonary insufficiency by protease inhibitor therapy with aprotinin: a clinical study. Circ Shock 1982; 9: 107-116.
39. 39 Emerson TE, Fournel MA, Redens TB, Taylor FB. Efficacy of antithrombin III supplementation in animal models of fulminant Escherichia coli endotoxemia or bacteremia. Am J Med 1989;187: (Suppl 3B), 27-33.
40. 40 Moldawer LL. Biology of proinflammatory cytokines and their antagonists. Crit Care Med 1994; 22: S3-S7.
41. 41 Suffredini AF. Current prospects for the treatment of clinical sepsis. Crit Care Med 1994; 22: S12-S18.